Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in Atrial Fibrillation III Randomised Clinical Trial

The Lancet

Volumn 348, Issue 9028, 1996, Pages 633-638

  Blackshear, J L ^a,x   Baker, V S ^a   Rubino, F ^a   Safford, R ^a   Lane, G ^a   Flipse, T ^a   Malouf, J ^a   Thompson, R ^a   Webel, R ^b   Flaker, G C ^b   Young, L ^b   Hess, D ^b   Friedman, G ^b   Burger, R ^b   McAnulty, J H ^c,x   Coull, B M ^c   Marchant, C ^c   Timberg, J ^c   Janzik, C ^c   Giraud, G ^c   Halperin, B ^c   Kron, J ^c   Wynn, M ^c   Raitt, M ^c   Anderson, D C ^d   Asinger, R W ^d   Newburg, S M ^d   Fifield, J ^d   Bundlie, S R ^d   Koller, R L ^d   Tarrel, R D ^d   Dick, C ^d   Haugland, J M ^d   Jorgensen, C R ^d   Leonard, A D ^e   Kanter, M C ^e   Solomon, D H ^e   Zabalgoitia, M ^e   Mego, D ^e   Carter, J E ^e   Boyd, S Y ^e   Boop, B S ^e   LaLonde, D ^e   Modlin, R ^e   Logan, W R ^f   Green, B J ^f   Hamilton, W P ^f   Mezei, L ^f   Riggio, S ^f   Feldman, G ^g   Hayward, A ^g   Strauss, R ^g   Anderson, W ^g   Grover, J ^g   McKenzie, M ^g   Hart McArthur, P ^g   Gramberg, M ^g   Houston, H ^g   Halperin, J L ^h,x   Rothauf, E B ^h   Weinberger, J M ^h   Goldman, M E ^h   Laupacis, A ^i,x   Chan, K L ⁱ   Bourque, P ⁱ   Biggs, J ⁱ   Ives, A ⁱ   Feinberg, W M ^j   Kern, K B ^j   Pennock, G D ^j   Fenster, P E ^j   Huerta, B J ^j   Ohm, J ^j   Dittrich, H C ^k   Kerridge, C ^k   Keen, W ^k   Swenson, M ^k   Kopecky, S L ^l   Litin, S C ^l   Wiebers, D O ^l   Holland, A E ^l   Brown, R D ^l   Khandheria, B K ^l   Meissner, I ^l   Tucker, K R ^l   Rothbart, R ^m   Torelli, J ^m   Schmidt, J ^m   Murray, D ^m   Ruzich, R S ⁿ   Loutfi, H ⁿ   Appleton, C ⁿ   Ingall, T ⁿ   Carlson, L ⁿ   Wilson, D ^o   Dunn, M ^o   Nolte, B ^o   Edwards, C ^o   Dick, A ^o   Price, L A ^o   Janosik, D L ^p   Bjerregaard, P ^p   Quattromani, A ^p   Schiller, L ^p   Labovitz, A ^p   Burch, C ^p   Parks, B J ^p   Thompson, D ^p   Berarducci, L ^p   Carey, S ^p   Vigil, A ^p   Falk, R ^q   Battinelli, N ^q   McNeil, M ^q   Davidoff, R ^q   Bernard, S ^q   Bergethon, P ^q   Fiori, L ^q   Albers, G ^r   Atwood, E ^r   Clark, J ^r   Tong, D ^r   Yenari, M ^r   Froelicker, V ^r   Lutsep, H ^r   Hock, N H ^r   Quaglietti, S ^r   Kemp, S ^r   Alpert, M A ^s   Rothrock, J F ^s   Hupp, C H ^s   Massey, C V ^s   Hamilton, W J ^s   Miller, V T ^t   Fox, J ^t   Kronmal, R A ^u   McBride, R ^v,x   Nasco, E ^v   Pearce, L A ^v   Fletcher, K ^v   Koehler, J ^v   Hart, R G ^e,x   Sherman, D G ^e   Talbert, R L ^e   Heberling, P A ^e   Kajzer, C ^e   Bovill, E ^w   Geffken, D ^w   Cornell, E ^w   Nightingale, S ^w   Kelsy, S P ^y   Levy, D E ^z   Marsh, J D ^aa   Welch, K M A ^ab   Marler, J R ^x   Walker, M D ^x   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PARK NICOLLET INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f ST JOHN S MERCY MEDICAL CENTER   (United States)

^g KAISER PERMANENTE   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j UNIVERSITY OF ARIZONA   (United States)

^k UCSD MEDICAL CENTER   (United States)

^l MAYO CLINIC   (United States)

^m LeBauer Cardiology Associates   (United States)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^p S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^q BOSTON MEDICAL CENTER   (United States)

^r VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^s UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^t MARSHFIELD CLINIC   (United States)

^u UNIVERSITY OF WASHINGTON   (United States)

^v Statistics and Epidemiology Research Corporation   (United States)

^w UNIVERSITY OF VERMONT   (United States)

^x University of Pittsburgh ^*

^y UNIVERSITY OF PITTSBURGH   (United States)

^z Knoll Pharmaceuticals   (United States)

^aa WAYNE STATE UNIVERSITY   (United States)

^ab HENRY FORD HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; COUMARIN ANTICOAGULANT; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

EID: 9544248668     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)03487-3     Document Type: Article

References (28)

1. 1 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
2. 2 EAFT Study Group. European Atrial Fibrillation Trial: secondary prevention of vascular events in patients with non-rheumatic atrial fibrillation and recent transient ischaemic attack or minor ischaemic stroke. Lancet 1993; 342: 1255-62.
3. 3 Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
4. 4 Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy for atrial fibrillation. Arch Intern Med 1996; 156: 409-16.
5. 5 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
6. 6 Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice. Arch Intern Med 1994; 154: 1945-53.
7. 7 Finn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-79.
8. 8 Gitter MJ, Jaeger TM, Petterson TN, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-33.
9. 9 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: Facts and hypotheses. Stroke 1995; 26: 1471-77.
10. 10 Shorr RI, Ray WA, Dougherty JR, Griffen MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high-risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-70.
11. 11 Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175-79.
12. 12 Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
13. 13 Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, and CAFA Study Co-investigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
14. 14 Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995; 5: 147-57.
15. 15 Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis (in press).
16. 16 Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
17. 17 Bussey JI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulant therapy Arch Intern Med 1992; 152: 278-82.
18. 18 Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology 1993; 43: 32-36.
19. 19 Bamford JM, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20: 828.
20. 20 Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989; 42: 711-18.
21. 21 Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies. Lyon: IARC, 1987.
22. 22 Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-46.
23. 23 Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988; 7: 1231-41.
24. 24 Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials 1989; 10: 209S-21S.
25. 25 Singer DE. Problems with stopping rules in trials of risky therapies: The case of warfarin to prevent stroke in atrial fibrillation. Clin Res 1993; 41: 482-86.
26. 26 European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
27. 27 Takano K, Lino K, Ibayashi S, Tagawa K, Sadoshima S, Fujishimia M. Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. Am J Cardiol 1994; 74: 935-39.
28. 28 Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996; 46: 238-40.